Clinigen Group PLC
LSE:CLIN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Clinigen Group PLC
LSE:CLIN
|
1.2B GBP |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
230.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
160.7B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.9T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.9B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.7B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.1B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.6B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.2B EUR |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
Clinigen Group PLC
Glance View
Clinigen Group PLC operates at the intersection of two pivotal sectors: pharmaceutical services and global supply. Founded in 2010, the company carved a niche for itself by navigating the intricate pathways of drug development and commercialization with precision. Clinigen's business model hinges on providing essential support to pharmaceutical and biotech companies, ensuring that life-saving medicines are distributed efficiently, even to the remotest parts of the world. At its core, Clinigen operates through two main segments: Unlicensed Medicines and Commercial Medicines. In the Unlicensed Medicines segment, Clinigen sources, develops, and supplies medications that haven't yet received formal approval in certain markets, often as a response to urgent or unmet patient needs. Their success largely rests on their ability to adapt quickly, driven by their deep knowledge of regulatory environments and robust logistics capabilities. In parallel, the Commercial Medicines segment acts as a critical growth driver for Clinigen. This arm involves the acquisition and licensing of niche pharmaceuticals, which the company then revitalizes, focusing on enhancing their market reach and operational efficiency. By capitalizing on these acquired products, Clinigen augments its revenue streams significantly. The company’s adeptness at identifying undervalued or underutilized drugs allows them to breathe new life into these assets, maximizing their commercial potential. The intricate dance between these segments illustrates Clinigen's strategic prowess. Their unique approach not only bolsters profitability but also underscores their commitment to making a tangible difference in the pharmaceutical landscape, by improving both availability and accessibility of crucial medications to those who need them most.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
Over the last 3 years, Clinigen Group PLC’s Operating Margin has decreased from 12% to 10.6%. During this period, it reached a low of 10.6% on Jan 31, 2022 and a high of 14.7% on Jun 30, 2020.